Back to Search
Start Over
Remnant cholesterol in the era of intensive lipid-lowering therapies.
- Source :
-
European heart journal [Eur Heart J] 2023 Sep 21; Vol. 44 (36), pp. 3483. - Publication Year :
- 2023
-
Abstract
- Competing Interests: Conflict of interest B.G.N. reports consultancies and talks sponsored by AstraZeneca, Sanofi, Regeneron, Akcea, Ionis, Amgen, Kowa, Denka, Amarin, Novartis, Novo Nordisk, Esperion, Abbott, and Silence Therapeutics. There are no competing interests for B.N.W., A.B.W., or K.M.P.
- Subjects :
- Humans
Cholesterol, LDL
Cholesterol
Subjects
Details
- Language :
- English
- ISSN :
- 1522-9645
- Volume :
- 44
- Issue :
- 36
- Database :
- MEDLINE
- Journal :
- European heart journal
- Publication Type :
- Report
- Accession number :
- 37322804
- Full Text :
- https://doi.org/10.1093/eurheartj/ehad298